Results 11 to 20 of about 73,633 (314)

Efficacy of losartan plus modified FOLFIRINOX versus modified FOLFIRINOX in advanced pancreatic cancers: A randomized clinical trial (AFPAC Study) [PDF]

open access: yesCancer, Volume 131, Issue 13, 1 July 2025.
Abstract Background The addition of angiotensin receptor blockers like losartan (L) has been shown to improve outcomes in small prospective studies of pancreatic ductal adenocarcinomas (PDAC). Methods Patients diagnosed with treatment‐naive locally advanced/metastatic PDAC with Eastern Cooperative Oncology Group performance status 0‐1 and adequate end‐
Anant Ramaswamy   +15 more
wiley   +2 more sources

Mitochondrial Calcium Uniporter‐Mediated Regulation of the SIRT3/GSK3β/β‐Catenin Signaling Pathway in Vascular Remodeling [PDF]

open access: yesThe FASEB Journal, Volume 39, Issue 13, 15 July 2025.
In HU and hypertensive rats, MCU expression in cerebral arteries is reduced. This reduction impairs cellular Ca2+ buffering and promotes mitochondrial oxidative stress. The stress response initiates the downstream degradation of SIRT3, which subsequently inhibits the activity of GSK3β via acetylation and promotes the nuclear translocation of β‐catenin,
Min Jiang   +9 more
wiley   +2 more sources

Losartan Alleviates Renal Fibrosis and Inhibits Endothelial-to-Mesenchymal Transition (EMT) Under High-Fat Diet-Induced Hyperglycemia

open access: yesFrontiers in Pharmacology, 2018
The endothelial-to-mesenchymal transition (EMT) of glomerular vascular endothelial cells is considered to be pivotal in diabetic nephropathy (DN).
Yufeng Yao   +5 more
doaj   +2 more sources

Optimizing Blood Pressure Control: A Randomized Comparative Trial of Losartan/Chlorthalidone vs. Losartan/Hydrochlorothiazide [PDF]

open access: yesCardiology and Therapy
Introduction Cardiovascular diseases are a leading cause of global mortality, with hypertension as a major risk factor. Low control rates are often attributed to monotherapy, while evidence and clinical guidelines support the effectiveness of combination
Isabel E. Rucker-Joerg   +8 more
doaj   +2 more sources

Angiotensin II Type 1 Receptor Blocker Usage Prevents Oxidative Stress and Muscle Dysfunction in HIV [PDF]

open access: yesFundamental &Clinical Pharmacology, Volume 39, Issue 4, August 2025.
ABSTRACT Background We aimed to elucidate the role of Angiotensin II type 1 receptor (AT1R) blocker usage in muscle wasting and dysfunction related to HIV. Research Design and Methods Appendicular skeletal muscle mass, higher and lower limb strength, and physical fitness were determined in people living with HIV (PWH) using AT1R blockers users (n = 33),
Rafael Deminice   +4 more
wiley   +2 more sources

Effects of losartan and atorvastatin on the development of early posttraumatic joint stiffness in a rat model

open access: yesDrug Design, Development and Therapy, 2019
Andreas Baranowski,1 Ludwig Schlemmer,1 Katharina Förster,1 Ekaterina Slotina,1 Tim Mickan,1 Sebastian Truffel,1 Anja Klein,1 Stefan G Mattyasovszky,1 Alexander Hofmann,1,2 Ulrike Ritz,1 Pol M Rommens11Department of Orthopaedics and Traumatology ...
Baranowski A   +10 more
doaj   +2 more sources

Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury

open access: yesJAMA Network Open, 2022
Key Points Question What is the effect of losartan on lung injury in hospitalized patients with COVID-19? Findings In this randomized clinical trial in 205 patients with evidence of COVID-19–induced acute lung injury, angiotensin receptor blockade with ...
M. Puskarich   +20 more
semanticscholar   +1 more source

Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury

open access: yesTranslational Vision Science & Technology, 2022
Purpose To evaluate the efficacy of losartan and prednisolone acetate in inhibiting corneal scarring fibrosis after alkali burn injury in rabbits. Methods Sixteen New Zealand White rabbits were included.
L. P. Sampaio   +4 more
semanticscholar   +1 more source

Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models

open access: yesbioRxiv, 2022
Immune checkpoint blockers (ICBs) have failed in all Phase III glioblastoma trials. Here, we found that ICBs induce cerebral edema in some patients and mice with glioblastoma.
Meenal Datta   +23 more
semanticscholar   +1 more source

Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma

open access: yesClinical Cancer Research, 2021
Purpose: There is increasing recognition that progress in immuno-oncology could be accelerated by evaluating immune-based therapies in dogs with spontaneous cancers. Osteosarcoma (OS) is one tumor for which limited clinical benefit has been observed with
D. Regan   +10 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy